Altruist Biologics has supported the acceptance and priority review of a multinational client's application to manufacture an existing overseas-developed biologic in China. The milestone demonstrates the relevance of China's 2024 localisation framework, but the client's identity, the medicine and the financial terms remain undisclosed.
Innovent Biologics will commercialize Daiichi Sankyo’s VANFLYTA in China after its June approval for newly diagnosed FLT3-ITD AML.
Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.
Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?
Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.
Innovent Biologics unveiled preclinical IBI3055 data in autoimmune disease. Read what this could change for immune-reset therapies.
Innovent Biologics’ efdamrofusp alfa cleared a key Phase 3 nAMD hurdle in China. Read what the STAR data could change for retinal treatment.
Innovent Biologics advances IBI354 into phase 3 first-line HER2-positive breast cancer. Find out what this means for ADC competition and clinical practice.
Ollin’s OLN324 outperformed faricimab in a head-to-head retinal trial. Find out how this could change first-line treatment in DME and wAMD.
Ollin Biosciences and Innovent Biologics have reported positive topline results from the randomized Phase 1b JADE trial, in which OLN324 (IBI324), a next-generation VEGF/Ang2 bispecific antibody, demonstrated superior anatomical efficacy over faricimab in patients with diabetic macular edema and wet age-related macular degeneration. Conducted in over 160 patients across the United States, the head-to-head study